Physician profile
Ammon J Larsen
NPI 1982044012
$620,182.50
in general payments reported to CMS, 2019-2025
33 companies · $299K in 2025
The $299K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,084 · 2020: $944 · 2021: $33K · 2022: $60K · 2023: $70K · 2024: $156K · 2025: $299K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $427K · Travel and Lodging: $34K · Consulting Fee: $32K · Food and Beverage: $18K · Honoraria: $14K · Education: $369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $427,039.10 |
| Travel and Lodging | $33,774.49 |
| Consulting Fee | $32,460.30 |
| Food and Beverage | $18,493.18 |
| Honoraria | $13,505.30 |
| Education | $368.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $169,594.59 | 2019-2025 | |
| Lilly USA, LLC | $142,141.03 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Ucb, INC. | $97,788.15 | 2021-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $80,243.76 | 2019-2025 | Nemluvio, Aklief |
| Genzyme Corporation | $58,685.56 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $31,429.92 | 2020-2025 | Dupixent |
| Organon LLC | $15,977.80 | 2025 | Vtama, Hadlima |
| Leo Pharma INC. | $11,582.29 | 2019-2025 | Anzupgo, Adbry, Spevigo |
| Pfizer INC. | $5,230.54 | 2019-2025 | |
| Incyte Corporation | $2,446.82 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $1,461.31 | 2019-2025 | Ilumya, Blu-U, Odomzo |
| Novartis Pharmaceuticals Corporation | $960.95 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $756.19 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $510.99 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| E.R. Squibb & Sons, L.L.C. | $305.16 | 2022-2025 | Sotyktu |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $202.05 | 2023-2024 | Vtama |
| Amgen INC. | $142.00 | 2020-2024 | Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $108.83 | 2019-2025 | Siliq |
| Allergan, INC. | $97.33 | 2019 | |
| Vyne Pharmaceuticals INC. | $87.84 | 2020-2021 | |
| Almirall LLC | $65.66 | 2021-2025 | Klisyri |
| Dermira, INC. | $63.53 | 2020-2021 | |
| Biocon Biologics INC | $54.58 | 2023-2024 | Hulio |
| Mylan Institutional INC. | $44.01 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.18 | 2022-2023 | Spevigo |
| Acera Surgical, INC. | $41.30 | 2021-2022 | |
| Promius Pharma LLC | $24.69 | 2019 | |
| Alnylam Pharmaceuticals INC. | $19.52 | 2020 | |
| Biofrontera INC. | $18.35 | 2025 | |
| Epi Health, LLC | $15.66 | 2020 | |
| Verrica Pharmaceuticals INC. | $15.63 | 2023 | Ycanth |
| Celgene Corporation | $12.49 | 2019 | |
| Journey Medical Corporation | $11.79 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ammon Larsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.